Post by
dmshediac on Jun 21, 2024 7:20am
"Strategic Review"
looks like he plan's on doing something with Vemowave, Inretio and or InStatin,, sell them off or spin them out as separate co.'s. , Reseach and development , hopefully some good "development, permant codes,, successfull development in Inretio,, etc, who knows, but some development news should be comimg JMO
Comment by
hk1966 on Jun 21, 2024 8:17am
Perhaps but would prefer he find a way to sell off non performing legacy assets like InterceptCS and Therozap and keep the newer investments like Instatin and Inretio.
Comment by
dmshediac on Jun 21, 2024 8:29am
i agree, clean up the non performing assets. Maybe Venowave will be a little good cash cow with sales , finally some regular revenue stream for the company. Keep it and sell the rest??? who knows, but we should get some knews soon, jmo